$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000122460824000050 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$1.130B	$1.066B
YoY Change	19.22%	2.07%
Cost Of Revenue	$726.2M	$568.8M
YoY Change	81.96%	0.51%
Gross Profit	$403.4M	$497.4M
YoY Change	-26.44%	3.91%
Gross Profit Margin	35.71%	46.65%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$851.6M
YoY Change		-3.96%
Operating Profit	$153.5M	$148.6M
YoY Change	18.26%	83.0%
Interest Expense	$68.00M	$64.20M
YoY Change	8.63%	-260.5%
% of Operating Profit	44.3%	43.2%
Other Income/Expense, Net
YoY Change
Pretax Income	$11.00M	$150.6M
YoY Change	-94.9%	56.71%
Income Tax	$1.700M	$34.30M
% Of Pretax Income	15.45%	22.78%
Net Earnings	$9.300M	$116.3M
YoY Change	-94.44%	57.8%
Net Earnings / Revenue	0.82%	10.91%
Basic Earnings Per Share	$0.09	$1.08
Diluted Earnings Per Share	$0.09	$1.06
COMMON SHARES
Basic Shares Outstanding	105.8M shares	108.3M shares
Diluted Shares Outstanding	107.1M shares	109.3M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$1.245B	$992.1M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$27.31B
YoY Change		7.75%
Other Assets		$882.8M
YoY Change		-12.34%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$37.65B	$36.29B
YoY Change	12.35%	6.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt		$4.523B
YoY Change		13.63%
Other Long-Term Liabilities		$937.6M
YoY Change		4.31%
Total Long-Term Liabilities		$5.460B
YoY Change		11.91%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities		$5.460B
Total Liabilities	$34.96B	$33.86B
YoY Change	10.56%	5.62%
SHAREHOLDERS EQUITY
Retained Earnings	$2.087B	$2.095B
YoY Change	10.98%	21.05%
Common Stock	$1.717B	$1.799B
YoY Change	-12.69%	-10.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.688B	$2.429B
YoY Change
Total Liabilities & Shareholders Equity	$37.65B	$36.29B
YoY Change	12.35%	6.57%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$9.300M	$116.3M
YoY Change	-94.44%	57.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		$110.9M
YoY Change		-21.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$1.146B
YoY Change		689.19%
Cash From Investing Activities		-$1.146B
YoY Change		689.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.377B
YoY Change		3066.21%
NET CHANGE
Cash From Operating Activities		110.9M
Cash From Investing Activities		-1.146B
Cash From Financing Activities		1.377B
Net Change In Cash		342.3M
YoY Change		760.05%
FREE CASH FLOW
Cash From Operating Activities		$110.9M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-17200000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	1832300000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	33861300000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109357540	shares
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36290200000	usd
CY2024Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	641500000	usd
CY2024Q2	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	351700000	usd
CY2024Q2	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	57400000	usd
CY2024Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-26300000	usd
CY2024Q2	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	9100000	usd
CY2024Q2	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	32800000	usd
CY2024Q2	us-gaap	Liability For Future Policy Benefit Remeasurement Gain Loss LiabilityForFuturePolicyBenefitRemeasurementGainLoss	30000000.0	usd
CY2024Q2	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	200000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	64200000	usd
CY2024Q2	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	61400000	usd
CY2024Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	251400000	usd
CY2024Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	915600000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	150600000	usd
CY2024Q2	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	34300000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	116300000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107731000	shares
CY2024Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	20200000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	4200000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000000.0	usd
CY2024Q2	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	501400000	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1100000	usd
CY2024Q2	us-gaap	Revenues Revenues	1066200000	usd
CY2024Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	568800000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109258000	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.06
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	116300000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-217100000	usd
CY2024Q2	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	-206800000	usd
CY2024Q2	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	-800000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-29700000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	132300000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2031800000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	73700000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-69100000	usd
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	17400000	usd
CY2023Q2	cno	Stock Based Compensation StockBasedCompensation	6800000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1995800000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2367700000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	116300000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000000.0	usd
CY2024Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	60000000.0	usd
CY2024Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	17500000	usd
CY2024Q2	cno	Stock Based Compensation StockBasedCompensation	6400000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2428900000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	72900000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	223800000	usd
	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	1150400000	usd
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	648300000	usd
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	105300000	usd
	cno	Insurance Policy Benefits InsurancePolicyBenefits	821400000	usd
	us-gaap	Interest Paid Net InterestPaidNet	108100000	usd
	cno	Policy Acquisition Costs PolicyAcquisitionCosts	186400000	usd
	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	537000000.0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	27700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	223400000	usd
	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	660300000	usd
	cno	Purchases Of Investments PurchasesOfInvestments	1906100000	usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-30800000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	22600000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-551900000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	34500000	usd
	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	889000000.0	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	106513566	shares
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1797600000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1464300000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2094500000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2428900000	usd
CY2023Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	30000000.0	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	45100000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	33800000	usd
	cno	Stock Based Compensation StockBasedCompensation	9200000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1995800000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2215600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	228600000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	112500000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000.0	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	33900000	usd
	cno	Stock Based Compensation StockBasedCompensation	6100000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2428900000	usd
	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	1164400000	usd
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	679000000.0	usd
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	89000000.0	usd
	cno	Insurance Policy Benefits InsurancePolicyBenefits	821000000.0	usd
	us-gaap	Interest Paid Net InterestPaidNet	122200000	usd
	cno	Policy Acquisition Costs PolicyAcquisitionCosts	214400000	usd
	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	523800000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	45500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	205500000	usd
	cno	Sales Of Investments SalesOfInvestments	1339200000	usd
	cno	Sales Of Investments SalesOfInvestments	747300000	usd
	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	967000000.0	usd
	cno	Purchases Of Investments PurchasesOfInvestments	3476000000	usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	6000000.0	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5700000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1169500000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	691000000.0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3800000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8600000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	118600000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55600000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	34500000	usd
	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	43000000.0	usd
	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	7100000	usd
	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	0	usd
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1856100000	usd
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1035700000	usd
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1007500000	usd
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	847600000	usd
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	237000000.0	usd
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	645500000	usd
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	237200000	usd
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	445500000	usd
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	315900000	usd
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	104100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1067100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	245500000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-83000000.0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	992100000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	867700000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	860900000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2272700000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2178700000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1738000000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1660600000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12614700000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10716600000	usd
CY2024Q2	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	17493100000	usd
CY2024Q2	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	15416800000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	7613000000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	7201100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	25106100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	22617900000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2246000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	28700000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10191300000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1403700000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12437300000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1432400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1169900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	24500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10886400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1365000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12056300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1389500000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	39000000.0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	2200000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-200000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	1200000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	39800000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	42900000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	4400000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-6200000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	1300000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	39800000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	59100000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	1900000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	6700000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	1600000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	66100000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	4900000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	7500000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	2300000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	66100000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	16600000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8400000	usd
CY2024Q2	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-3400000	usd
CY2023Q2	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1900000	usd
CY2024Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13200000	usd
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10300000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	15400000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-2200000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	2300000	usd
CY2024Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13200000	usd
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10300000	usd
CY2024Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-26300000	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-21800000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-36300000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-36400000	usd
CY2024Q2	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-4100000	usd
CY2023Q2	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	9900000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-5600000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	11400000	usd
CY2024Q2	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-700000	usd
CY2023Q2	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	0	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	200000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	400000	usd
CY2024Q2	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	5700000	usd
CY2023Q2	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-3600000	usd
	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	17300000	usd
	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-2500000	usd
CY2024Q2	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	0	usd
CY2023Q2	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	0	usd
	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	0	usd
CY2024Q2	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	9100000	usd
CY2023Q2	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-13500000	usd
	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	26900000	usd
	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-13500000	usd
CY2024Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-17200000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-35300000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-9400000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-49900000	usd
CY2024Q2	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1500000	usd
CY2023Q2	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	1000000.0	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-300000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1000000.0	usd
CY2024Q2	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-700000	usd
CY2023Q2	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-500000	usd
	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	300000	usd
	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	100000	usd
CY2024Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0	usd
CY2023Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-3100000	usd
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	4700000	usd
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-5600000	usd
	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-5600000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-49900000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	11400000	usd
CY2024Q2	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	669200000	usd
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	388800000	usd
CY2024Q2	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2465900000	usd
CY2023Q2	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2601700000	usd
CY2024Q2	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	66800000	usd
CY2023Q2	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	59900000	usd
CY2024Q2	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	215700000	usd
CY2023Q2	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	448700000	usd
CY2024Q2	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	31100000	usd
CY2023Q2	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34700000	usd
CY2024Q2	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11479400000	usd
CY2023Q2	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11479600000	usd
CY2023Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-68000000.0	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2023Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	4800000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2023Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-63200000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	100000	usd
	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-100000	usd
	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	10200000	usd
	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	10700000	usd
	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-19400000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	4200000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	-3800000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	9700000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-1000000.0	usd
	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-25300000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	4100000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	1800000	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-4100000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-3900000	usd
CY2024Q2	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-77100000	usd
CY2023Q2	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-44700000	usd
CY2024Q2	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	4200000	usd
CY2023Q2	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	10800000	usd
CY2024Q2	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-81300000	usd
CY2023Q2	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-55500000	usd
CY2024Q2	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2023Q2	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2024Q2	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-81300000	usd
CY2023Q2	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-55500000	usd
CY2024Q2	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	84500000	usd
CY2023Q2	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	66000000.0	usd
CY2024Q2	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	3200000	usd
CY2023Q2	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	10500000	usd
CY2024Q2	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-81300000	usd
CY2023Q2	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-55500000	usd
CY2024Q2	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	50000000.0	usd
CY2023Q2	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	52000000.0	usd
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P69Y
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P69Y
	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	1204700000	usd
	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	1186900000	usd
	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	240800000	usd
	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	239400000	usd
CY2024Q2	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	10171400000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2024Q2	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	10171400000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2024Q2	us-gaap	Policyholder Funds PolicyholderFunds	16637900000	usd
CY2023Q2	us-gaap	Policyholder Funds PolicyholderFunds	15387700000	usd
CY2024Q2	us-gaap	Policyholder Funds PolicyholderFunds	16637900000	usd
CY2023Q2	us-gaap	Policyholder Funds PolicyholderFunds	15387700000	usd
CY2023Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1851300000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	187700000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	104300000	usd
CY2024Q2	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1934700000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	175100000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	94000000.0	usd
CY2023Q2	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1771500000	usd
CY2023Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	180700000	usd
	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	10300000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	11900000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	116300000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	116300000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	73700000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	73700000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	228600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	228600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	72900000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	72900000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107731000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114273000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108347000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114409000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1527000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1377000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1705000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1780000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109258000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115650000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110052000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116189000	shares
	cno	Numberof Product Lines NumberofProductLines	3	product_line
	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2024Q2	cno	Segment Revenues SegmentRevenues	1074300000	usd
CY2023Q2	cno	Segment Revenues SegmentRevenues	1039900000	usd
	cno	Segment Revenues SegmentRevenues	2211000000	usd
	cno	Segment Revenues SegmentRevenues	2040400000	usd
CY2024Q2	cno	Segment Expenses SegmentExpenses	925700000	usd
CY2023Q2	cno	Segment Expenses SegmentExpenses	958700000	usd
	cno	Segment Expenses SegmentExpenses	1987600000	usd
	cno	Segment Expenses SegmentExpenses	1882800000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	148600000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	81200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	223400000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	157600000	usd
CY2024Q2	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	34000000.0	usd
CY2023Q2	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	18900000	usd
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	51300000	usd
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	36700000	usd
CY2024Q2	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	114600000	usd
CY2023Q2	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	62300000	usd
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	172100000	usd
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	120900000	usd
CY2024Q2	us-gaap	Revenues Revenues	1066200000	usd
CY2023Q2	us-gaap	Revenues Revenues	1022800000	usd
	us-gaap	Revenues Revenues	2222700000	usd
	us-gaap	Revenues Revenues	2028800000	usd
CY2024Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	915600000	usd
CY2023Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	926700000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1925900000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1933700000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	150600000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	96100000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	296800000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	95100000	usd
CY2024Q2	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	34300000	usd
CY2023Q2	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	22400000	usd
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	68200000	usd
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	22200000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	116300000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	73700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	228600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	72900000	usd
CY2024Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	78000000	usd
CY2024Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	38800000	usd
CY2023Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	59600000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	179300000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	79600000	usd
CY2024Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	28500000	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	36400000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	101100000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-8500000	usd
CY2024Q2	us-gaap	Ceded Premiums Written CededPremiumsWritten	46600000	usd
CY2023Q2	us-gaap	Ceded Premiums Written CededPremiumsWritten	49700000	usd
	us-gaap	Ceded Premiums Written CededPremiumsWritten	92600000	usd
	us-gaap	Ceded Premiums Written CededPremiumsWritten	98000000.0	usd
CY2024Q2	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	89800000	usd
CY2023Q2	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	86900000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	195600000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	221800000	usd
CY2024Q2	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	3800000	usd
CY2023Q2	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4300000	usd
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	7900000	usd
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	8400000	usd
CY2024Q2	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	7100000	usd
CY2023Q2	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	5800000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	13000000.0	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	10500000	usd
CY2024Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9300000	usd
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	19700000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	26600000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	33700000	usd
CY2024Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25000000.0	usd
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2700000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	41600000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11500000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34300000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22400000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68200000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22200000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.230
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.233
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	255400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	77100000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	41100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	346000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	322800000	usd
CY2024Q2	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	0	usd
CY2023Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	252900000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	414800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	445500000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	20200000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35600000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1077500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1136400000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	38700000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	36300000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	173800000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	163000000.0	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	212500000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	199300000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	865000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	937100000	usd
CY2024Q2	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	17800000	usd
CY2023Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	-900000	usd
CY2024Q2	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	882800000	usd
CY2023Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	936200000	usd
CY2024Q2	cno	Tax Loss Carryforward Impact Of Change In Tax Method Accounting TaxLossCarryforwardImpactOfChangeInTaxMethodAccounting	985000000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P39Y
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	865000000.0	usd
CY2024Q2	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2024Q2	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2024Q2	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0362
CY2024Q2	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2024Q2	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	1216300000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	41100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	15400000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	9500000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	1832300000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	1140500000	usd
	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	62800000	usd
	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	45900000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000.0	usd
CY2024Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	421800000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	33900000	usd
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.31
CY2024Q2	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1320400000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1235200000	usd
CY2024Q2	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1140500000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-931000000.0	usd
CY2024Q2	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	571900000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	133400000	usd
CY2024Q2	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	4200000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	4800000	usd
CY2024Q2	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	420500000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	451200000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1464300000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1576800000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) ("PPVA"), the Joint Official Liquidators of PPVA (the "JOLs") and Principal Growth Strategies, LLC, ("PGS"), commenced suit against, among others, CNO Financial Group, Inc., Bankers Conseco Life Insurance Company ("BCLIC"), Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. On December 1, 2023, the Delaware Chancery Court lifted the stay as of November 30, 2023. On January 25, 2024, the Delaware Chancery Court granted in part and denied in part the CNO Parties’ motion to dismiss the Amended Complaint. Based on the Court’s ruling, PPVA and the JOLs’ claims against the CNO Parties were dismissed. On April 9, 2024, PGS filed a second amended complaint, which contains the same claims against the CNO Parties that PGS had previously asserted. The CNO Parties are vigorously contesting PGS's claims.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana. On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div>
CY2022Q1	cno	Number Of Policyholders NumberOfPolicyholders	2000	policyholder
	us-gaap	Net Income Loss NetIncomeLoss	228600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	72900000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	141900000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131900000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22700000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5500000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	222400000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	259600000	usd
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-199200000	usd
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-94400000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	214400000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	186400000	usd
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-9400000	usd
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-49900000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-5900000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-4600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	205500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	223400000	usd
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	12100000	usd
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	13000000.0	usd
CY2024Q2	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	440600000	usd
CY2024Q2	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	1300000	usd
CY2024Q2	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	-13600000	usd
CY2024Q2	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	2800000	usd
CY2024Q2	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	425500000	usd
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-5700000	usd
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-9800000	usd
	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-300000	usd
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	10600000	usd
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	103100000	usd
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-4000000.0	usd
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-5000000.0	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1000000.0	usd
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	5200000	usd
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	11000000.0	usd
CY2024Q2	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2024Q2	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	477800000	usd
CY2024Q2	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	398100000	usd
	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.92
CY2024Q2	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.73
CY2024Q2	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.83
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001224608-24-000050-index-headers.html	Edgar Link	pending
0001224608-24-000050-index.html	Edgar Link	pending
0001224608-24-000050.txt	Edgar Link	pending
0001224608-24-000050-xbrl.zip	Edgar Link	pending
cno-20240630.htm	Edgar Link	pending
cno-20240630.xsd	Edgar Link	pending
cno-20240630_cal.xml	Edgar Link	unprocessable
cno-20240630_def.xml	Edgar Link	unprocessable
cno06302024ex311.htm	Edgar Link	pending
cno06302024ex312.htm	Edgar Link	pending
cno06302024ex321.htm	Edgar Link	pending
cno06302024ex322.htm	Edgar Link	pending
exhibit32-byxlaws.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
cno-20240630_pre.xml	Edgar Link	unprocessable
cno-20240630_lab.xml	Edgar Link	unprocessable
cno-20240630_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2024 Q3 Form 10-Q Financial Statement

#000122460824000050 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2024 Q3 Form 10-Q Financial Statement

#000122460824000050 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno